SCHEMBL4479319

SCHEMBL4479319

Cc1ccc(Cn2nc3ccccc3c2-c2ccc(C)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
CYP1A2 P05177 2/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
PTGER4 P35408 1/20 0.51
NR1H2 P55055 4/20 0.48
NR1H3 Q13133 4/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 2/20 0.48
SCN8A Q9UQD0 1/20 0.45
TP53 P04637 1/20 0.44
HTT P42858 3/20 0.44
LMNA P02545 2/20 0.44
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4494497 0.95 ALDH1A1 (0.53) SMN1; SMN2CYP1A2NPC1RAB9ACYP3A4
SCHEMBL4482187 0.94 NR1H2 (0.52) SMN1; SMN2CYP1A2NPC1RAB9ACYP3A4
SCHEMBL27669279 0.93 CYP1A2 (0.49) SMN1; SMN2CYP1A2NPC1RAB9ACYP3A4
SCHEMBL4478557 0.91 HTT (0.56) SMN1; SMN2CYP1A2NPC1RAB9ACYP3A4
SCHEMBL4476567 0.87 MAPT (0.58) SMN1; SMN2CYP1A2NPC1RAB9ACYP3A4
SCHEMBL4487606 0.84 NR1H2 (0.56) SMN1; SMN2RAB9ANR1H2NR1H3MEN1
SCHEMBL4489322 0.84 NR1H2 (0.46) SMN1; SMN2CYP1A2NPC1RAB9ANR1H2
SCHEMBL4485895 0.82 CYP1A2 (0.49) SMN1; SMN2CYP1A2NPC1RAB9ACYP3A4
SCHEMBL27688464 0.82 CYP1A2 (0.59) SMN1; SMN2CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL27669290 0.80 L3MBTL1 (0.56) SMN1; SMN2CYP1A2NPC1RAB9ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514465-B2 Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents YUNG SHIN PHARM. IND. CO., LTD. (TW) 2009-04-07 US disclosed
EP-1659115-A1 Synthesis of substituted 2H-indazole derivatives as anti-angiogenic agents Yung Shin Pharm. Ind. Co., Ltd. (TW) 2006-05-24 EP disclosed
US-20060106032-A1 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents YUNG SHIN PHARM. IND. CO., LTD. (TW) 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106032-A1 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents FLT4, FLT1, KDR SMN1; SMN2 2932/4885CYP1A2 1288/4885NPC1 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.